Counterfeiting, Compliance, and Controls

FDA and manufacturers seek to curb drug counterfeiting while legislators consider liberalizing drug importing policies to cut pharmaceutical costs.

Related Content:

Regulatory WatchSupply ChainAnticounterfeiting, Track and Trace SystemsPharmaceutical Technology-09-02-2003

FDA In Limbo as User Fee Renewal Stuck on Capitol Hill

Will Remote Pharma GMP Auditing Endure Post-Pandemic?

Reducing Blind Spots in the Pharma Supply Chain